Clinical Trial Update: Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine [Phase 2]

View source ↗

Summary

Phase 2 trial update on MP-12 Rift Valley Fever vaccine reporting safety, immunogenicity, and genetic drift findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rift Valley Fever

Drugs mentioned

• MP-12 Rift Valley Fever vaccine

Snippet

Sponsor: U.S. Army Medical Research and Development Command | Conditions: Rift Valley Fever | Phase 2 | Status: COMPLETED | Results posted: 2017-02-01